Opportunities
Browse government tenders, quotations, vacancies and documents across South Africa.
Showing opportunities with a recorded closing date that has not passed. Choose another status to browse historical records.
A holder of a valid Category A licence to manufacture, import or export medicines must have the relevant complementary medicines approved and included on the applicable product list through the DA02 amendment process, because no separate Category D licence is issued for complementary medicines. For bid evaluation the licence is considered together with the corresponding DA02 Product List.
- Who it is for:
- holders of a valid Category A licence to manufacture, import or export medicines, and applicants or bidders offering complementary medicines
- How to act on it:
- The Category A licence holder has the complementary medicines approved and included on the applicable product list through the DA02 amendment process with SAHPRA, and submits the licence with all applicable annexures and product lists in the bid
Where the name of a product offered in a bid or marketed by an applicant differs from the name on the applicable DA02 Product List, the difference is not assumed to be merely administrative, stylistic or non-material. The change must be submitted to SAHPRA for review and approval, as it may relate to a formulation change, intended-use change or product-name change.
- Who it is for:
- applicants and bidders whose offered or marketed product name differs from the name on the applicable DA02 Product List
- How to act on it:
- Submit the product change to SAHPRA for review and approval
The National Department of Health is seeking to appoint a service provider to support the ongoing improvement and maintenance of health facilities across clinics, community health centres, and district hospitals. The service provider will focus on quality improvement initiatives, supportive supervision, mentorship, and patient-centred care implementation over a three-year period.
- Who it is for:
- qualified service providers with experience in public health quality improvement programmes in primary healthcare facilities
- How to act on it:
- Submit a bid package including a budget estimate, updated evaluation criteria documentation, reference letters, completion letters, and CVs of key personnel with relevant qualifications and experience.
The Department of Health is seeking suppliers to provide a multivalent vaccine containing diphtheria toxoid, tetanus toxoid, acellular pertussis, inactivated polio vaccine, Haemophilus influenza b, and hepatitis B. The pack size has been amended from 1 x 10 prefilled syringes to 1 x 10 single dose vials.
- Who it is for:
- suppliers of vaccines, specifically The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd
- How to act on it:
- Submit a bid or proposal in response to the contract amendment as per tender procedures
The Department of Health requires a multidose vaccine containing at least 1000 CCID50 of live attenuated measles and 1000 CCID50 of live attenuated rubella virus per 0.5ml. The pack size has been changed from 1 x 50 vials to 1 x 1 vial, and the minimum order quantity has been reduced from 50 to 10 vials.
- Who it is for:
- suppliers of vaccines, specifically The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd
- How to act on it:
- Submit a bid or proposal in response to the contract amendment as per tender procedures
Adcock Ingram Critical Care (Pty) Ltd is approved to supply 75,000 units of an alternative brand of Oxytocin 5iu, Ergometrine 0.5mg injection, which is registered in the United Kingdom, due to a current stockout of the original product. This approval allows them to deliver the alternative product to the Department of Health.
- Who it is for:
- Adcock Ingram Critical Care (Pty) Ltd
- How to act on it:
- No action required by external parties. The approval is issued directly to the supplier to proceed with delivery of the alternative product.
Medi-Challenge (Pty) Ltd is approved to supply an alternative version of Mifepristone 200mg tablets, which are packaged in French or Romanian, due to the current unavailability of the original brand (Mifegyne 200mg). This approval allows the continuation of supply under the existing contract without interruption.
- Who it is for:
- Medi-Challenge (Pty) Ltd
- How to act on it:
- No action required; the approval is granted directly to the supplier under contract.
Austell Pharmaceuticals (Pty) Ltd is unable to supply its own brand of Enalapril 5mg scored tablets. The Department of Health has approved a replacement brand, Enalapril 5mg Arya 28's, to be supplied between August 2026 and 31 October 2026 as part of the ongoing contract for solid dosage forms.
- Who it is for:
- Austell Pharmaceuticals (Pty) Ltd
- How to act on it:
- No action required by external parties; this is an internal procurement adjustment confirmed by the Department of Health.
The Department of Health has approved an emergency supply of 614,489 units of Luvigen tablets, which are an alternative brand to VULANTE TAB BOT 28 TND, for use in the national anti-retroviral programme.
- Who it is for:
- Pharmacare Limited and other approved pharmaceutical suppliers
- How to act on it:
- No action required by external parties; the approval is internal and directed to the supplier already named.
The Department of Health is instructing suppliers to update the National Stock Number (NSN) for item 47, which is an inhaler device with mask and spacer for infants, from 189750639 to 189750638. This change applies to the current contract cycle and must be implemented by all relevant parties.
- Who it is for:
- pharmaceutical suppliers under contract HP07-2026DAI, specifically Glenmark Pharmaceuticals SA (Pty) Ltd
- How to act on it:
- No action required by external parties; internal update for procurement and supply chain management
This is a government contract for the supply and delivery of anti-retroviral medicines to the Department of Health, covering the period from 1 December 2025 to 30 November 2028. The contract includes a brand name change for one product from ODINSTI DISPERSIBLE to MYLTEGA 10mg DISPERSIBLE TABLETS.
- Who it is for:
- approved pharmaceutical suppliers with existing contracts with the Department of Health
- How to act on it:
- No action required by external parties; this is an internal contract amendment documented for transparency.
The Department of Health has revised the prices for certain medicines supplied by Austell Pharmaceuticals (Pty) Ltd. These updated prices are effective immediately and must be reflected in all relevant records. The changes apply to Allopurinol, Ibuprofen, and Paracetamol tablets.
- Who it is for:
- Austell Pharmaceuticals (Pty) Ltd and related procurement officials
- How to act on it:
- Update internal records to reflect the revised prices as stated in this addendum